Recursion Pharmaceuticals Second Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags

Recursion Pharmaceuticals (NASDAQ:RXRX) Second Quarter 2025 Results

Key Financial Results

• Revenue: US$19.2m (up 33% from 2Q 2024).
• Net loss: US$171.9m (loss widened by 76% from 2Q 2024).
• US$0.41 loss per share (further deteriorated from US$0.40 loss in 2Q 2024).

This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality.

All figures shown in the chart above are for the trailing 12 month (TTM) period

Recursion Pharmaceuticals Revenues Beat Expectations, EPS Falls Short

Revenue exceeded analyst estimates by 25%. Earnings per share (EPS) missed analyst estimates by 26%.

Looking ahead, revenue is forecast to grow 41% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Biotechs industry in the US.

Performance of the American Biotechs industry.

The company's shares are down 7.1% from a week ago.

Risk Analysis

Before we wrap up, we've discovered 3 warning signs for Recursion Pharmaceuticals (1 is potentially serious!) that you should be aware of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.